Aliri
Private Company
Funding information not available
Overview
Aliri Bioanalysis is a specialized, service-based CRO providing integrated bioanalytical and spatial services to accelerate drug development. The company leverages a sophisticated technology platform combining liquid chromatography-mass spectrometry (LC-MS), imaging mass cytometry, and digital spatial profiling to deliver PK, PD, and biomarker data with spatial context. With over 30 years of collective experience and serving 300+ pharma and biotech customers, Aliri positions itself as a partner for de-risking candidates and making data-driven decisions from pre-clinical toxicology to late-stage clinical trials.
Technology Platform
Integrated platform combining advanced bioanalytical services (LC-MS, LC-HR/MS, qPCR, CyTOF) with spatial biology services (Imaging Mass Cytometry, Quantitative MS Imaging, Digital Spatial Profiling, Visium) and AI-driven data analysis to provide PK, PD, and biomarker data with tissue context.
Opportunities
Risk Factors
Competitive Landscape
Aliri competes in the fragmented bioanalytical CRO market against large, full-service CROs (e.g., LabCorp, IQVIA, PPD) and numerous specialized boutiques. Its key differentiation is the deep integration of spatial biology and tissue context with traditional quantitative bioanalysis, a niche less served by larger, more generalized competitors.